Secukinumab is: (A) Anti IL 1, (B) Anti IL 6, (C) Anti IL 17, (D) Anti IL 23
Answer is C. Ustekinumab (anti-IL-12/23) and secukinumab (anti-IL-17) monoclonal antibodies have shown promising efficacy in clinical trials, but have not yet been approved for use in Ankylosing Spondylitis. Reference: Harrison&;s Principles of Internal Medicine; kd tripathi 9th ed